Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)
Dental and Pharmaceutical Benefits Agency (TLV)
Record ID 32018001140
English
Authors' objectives:
This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)”.
Details
Project Status:
Completed
Year Published:
2018
URL for published report:
https://eunethta.eu/wp4-ptja03-on-alectinib-alecensa-as-monotherapy-for-the-first-line-treatment-of-adult-patients-with-alk-positive-advanced-non-small-cell-lung-cancer-nsclc-is-now-available/
Requestor:
HTA agencies
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
MeSH Terms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Adult
- Tyrosine Kinase Inhibitors
Contact
Organisation Name:
European Network for Health Technology Assessment
Contact Email:
eunethta@zinl.nl
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.